Department of Orthopedic Surgery, Affiliated Hospital of Qingdao University, Qingdao, 266000, China.
Department of Orthopedic Surgery, Qingdao Municipal Hospital (Group), Qingdao, 266011, China.
BMC Cancer. 2020 Dec 3;20(1):1187. doi: 10.1186/s12885-020-07687-3.
MNAT1 (menage a trois 1, MAT1), a cyclin-dependent kinase-activating kinase (CAK) complex, highly expressed in diverse cancers and was involved in cancer molecular pathogenesis. However, its deliverance profile and biological function in osteosarcoma (OS) remain unclear.
The expression of MNAT1 in OS was detected by western blot (WB) and immunohistochemistry (IHC). The potential relationship between MNAT1 molecular level expression and OS clinical expectations were analyzed according to tissues microarray (TMA). Proliferation potential of OS cells was evaluated in vitro based on CCK8 and OS cells colony formation assays, while OS cells transwell and in situ tissue source wound healing assays were employed to analyze the OS cells invasion and migration ability in vitro. A nude mouse xenograft model was used to detect tumor growth in vivo. In addition, ordinary bioinformatics analysis and experimental correlation verification were performed to investigate the underlying regulation mechanism of OS by MNAT1.
In this research, we found and confirmed that MNAT1 was markedly over-expressed in OS tissue derived in situ, also, highly MNAT1 expression was closely associated with bad clinical expectations. Functional studies had shown that MNAT1 silencing could weaken the invasion, migration and proliferation of OS cells in vitro, and inhibit OS tumor growth in vivo. Mechanism study indicated that MNAT1 contributed to the progression of OS via the PI3K/Akt/mTOR pathway. We further verified that the MNAT1 was required in the regulation of OS chemo-sensitivity to cisplatin (DDP).
Taken together, the data of the present study demonstrate a novel molecular mechanism of MNAT1 involved in the formation of DDP resistance of OS cells.
MNAT1(menage a trois 1,MAT1)是一种细胞周期蛋白依赖性激酶激活激酶(CAK)复合物,在多种癌症中高表达,参与癌症的分子发病机制。然而,其在骨肉瘤(OS)中的递呈谱和生物学功能尚不清楚。
采用 Western blot(WB)和免疫组织化学(IHC)检测 OS 中 MNAT1 的表达。根据组织微阵列(TMA)分析 MNAT1 分子水平表达与 OS 临床预期的潜在关系。基于 CCK8 和 OS 细胞集落形成实验评估 OS 细胞的增殖潜力,通过 OS 细胞 Transwell 和原位组织源伤口愈合实验分析 OS 细胞的体外侵袭和迁移能力。建立裸鼠异种移植模型检测体内肿瘤生长。此外,通过普通生物信息学分析和实验相关性验证,研究 MNAT1 对 OS 的潜在调控机制。
本研究发现并证实 MNAT1 在原位 OS 组织中明显过表达,并且高 MNAT1 表达与不良临床预后密切相关。功能研究表明,MNAT1 沉默可减弱 OS 细胞的体外侵袭、迁移和增殖能力,并抑制体内 OS 肿瘤生长。机制研究表明,MNAT1 通过 PI3K/Akt/mTOR 通路促进 OS 的进展。我们进一步验证了 MNAT1 在调节 OS 对顺铂(DDP)的化疗敏感性中起作用。
综上所述,本研究数据表明 MNAT1 在 OS 细胞形成 DDP 耐药性的过程中涉及一种新的分子机制。